iSpecimen Amends S-1/A for Auditor Consent; 1.56M Shares for Resale

TL;DR

**ISPC's S-1/A is a procedural step for existing investors to dump shares, signaling potential dilution pressure on the $1.18 stock, so tread carefully.**

AI Summary

iSpecimen Inc. (ISPC) filed an S-1/A on August 25, 2025, primarily to include the consent of its former independent registered public accounting firm, Wolf & Company, P.C., as Exhibit 23.1. This amendment does not introduce new financial results but pertains to the registration of 1,559,828 shares of common stock for resale by selling stockholders. This total includes 267,379 shares and 1,292,449 shares issuable upon exercise of pre-funded warrants from an August 2025 Private Placement. The company will not receive proceeds from the sale of these shares by selling stockholders, but may receive up to $0.0001 per share upon warrant exercise. iSpecimen operates a global marketplace platform connecting researchers to biospecimens and data, aiming to transform biospecimen procurement. The company is an 'emerging growth company' and its common stock trades on the Nasdaq Capital Market under 'ISPC', with a last reported sale price of $1.18 per share on August 18, 2025. Future plans include enhancing customer experience, increasing supplier engagement, and improving operational efficiency of its platform.

Why It Matters

This S-1/A filing is crucial for investors as it facilitates the resale of 1,559,828 shares by selling stockholders, potentially increasing the float and impacting ISPC's stock price, which was $1.18 on August 18, 2025. While iSpecimen won't directly benefit from these sales, the successful registration is a step towards liquidity for early investors from the August 2025 Private Placement. For customers and the broader market, iSpecimen's mission to create an 'Amazon-like' global marketplace for biospecimens addresses a fragmented market, aiming to accelerate life science research and potentially disrupt traditional procurement methods. The company's focus on enhancing its platform and exploring 'data as a product' models positions it competitively in the growing biotech research support sector.

Risk Assessment

Risk Level: medium — The risk level is medium because the filing explicitly states that iSpecimen will not receive any proceeds from the sale of 1,559,828 shares by selling stockholders, which could lead to significant dilution if all shares are sold. While the company may receive up to $0.0001 per share upon warrant exercise, this is a nominal amount and does not offset the potential selling pressure. The company also highlights numerous forward-looking statements that involve 'numerous risks and uncertainties' in its 'Special Note Regarding Forward-Looking Statements' section.

Analyst Insight

Investors should monitor the trading volume and price action of ISPC closely following the effectiveness of this registration statement, as the resale of 1,559,828 shares could create downward pressure on the stock. Consider the potential for dilution and the company's limited direct financial benefit from these sales when evaluating entry or exit points. Focus on future operational updates and actual revenue generation from their marketplace platform.

Key Numbers

• 1,559,828 — Shares of Common Stock (Total shares offered for resale by selling stockholders)
• 267,379 — Shares of Common Stock (Direct shares held by selling stockholders for resale)
• 1,292,449 — Warrant Shares (Shares issuable upon exercise of pre-funded warrants for resale)
• $0.0001 — Nominal exercise price per share (Exercise price for pre-funded warrants)
• $1.18 — Last reported sale price for common stock (As of August 18, 2025, on the Nasdaq Capital Market)
• 1-for-20 — Reverse stock split ratio (Effected on September 13, 2024)
• August 25, 2025 — Filing Date (Date of Amendment No. 1 to Form S-1)
• July 31, 2025 — Date of Purchase Agreement (For the August 2025 Private Placement)

Key Players & Entities

• iSpecimen Inc. (company) — Registrant and operator of biospecimen marketplace
• Wolf & Company, P.C. (company) — Former independent registered public accounting firm whose consent is being included
• Katharyn Field (person) — President and agent for service for iSpecimen Inc.
• Ross D. Carmel, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
• Barry P. Biggar, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
• Benjamin E. Sklar, Esq. (person) — Counsel from Sichenzia Ross Ference Carmel LLP
• Securities and Exchange Commission (regulator) — Regulatory body overseeing the S-1/A filing
• Nasdaq Capital Market (regulator) — Stock exchange where ISPC common stock is listed
• Sichenzia Ross Ference Carmel LLP (company) — Legal counsel for iSpecimen Inc.

FAQ

Key Financial Figures

• $0.0001 — 9,828 shares of common stock, par value $0.0001 per share, of iSpecimen, Inc., held by
• $0 — t a nominal exercise price per share of $0.0001, without expiration, all of which
• $1.18 — ted sale price for our common stock was $1.18 per share. We are an "emerging growth

Filing Documents

• ea0254292-s1a1_ispecimen.htm (S-1/A) — 2087KB
• ea025429201ex23-1_ispecimen.htm (EX-23.1) — 2KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 4KB
• 0001213900-25-080408.txt ( ) — 9203KB
• ispc-20250630.xsd (EX-101.SCH) — 71KB
• ispc-20250630_cal.xml (EX-101.CAL) — 90KB
• ispc-20250630_def.xml (EX-101.DEF) — 411KB
• ispc-20250630_lab.xml (EX-101.LAB) — 670KB
• ispc-20250630_pre.xml (EX-101.PRE) — 440KB
• ea0254292-s1a1_ispecimen_htm.xml (XML) — 1159KB

Use of Proceeds

Use of Proceeds 33 Dividend Policy 33

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 33

Business

Business 47 Management 61

Executive Compensation

Executive Compensation 66 Certain Relationships and Related Party Transactions 73 Principal Stockholders 74

Description of Securities

Description of Securities 75 August 2025 Private Placement 77 Selling Stockholders 78 Plan of Distribution 79 Legal Matters 80 Experts 80 Where You Can Find More Information 80 Index to Financial Statements F-1 i ABOUT THIS PROSPECTUS This prospectus describes the general manner in which the Selling Stockholders may offer from time to time the Shares and Warrant Shares. You should rely only on the information contained in this prospectus and the related exhibits, any prospectus supplement or amendment thereto and the documents incorporated by reference, or to which we have referred you, before making your investment decision. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. If anyone provides you with different or inconsistent information, you should not rely on it. This prospectus, any prospectus supplement or amendments thereto do not constitute an offer to sell, or a solicitation of an offer to purchase, the common stock offered by this prospectus, any prospectus supplement or amendments thereto in any jurisdiction to or from any person to whom or from whom it is unlawful to make such offer or solicitation of an offer in such jurisdiction. You should not assume that the information contained in this prospectus, any prospectus supplement or amendments thereto, as well as information we have previously filed with the U.S. Securities and Exchange Commission (the "SEC"), is accurate as of any date other than the date on the front cover of the applicable document. If necessary, the specific manner in which the shares of common stock may be offered and sold will be described in a supplement to this prospectus, which supplement may also add, update or change any of the information contained in this prospectus. To the extent there is a conflict between the information contained in this prospectus and any prospectus supplement, you should rely on the information in such prospectus

forward-looking statements include statements relating to

forward-looking statements include statements relating to: our ability to enter into contracts with healthcare providers to gain access to specimens, subjects, and data on favorable terms; our ability to obtain new customers and keep existing customers; development of our technology to adequately keep pace to support expansion of our existing line of business or our entry into new lines of businesses; market adoption rate of our marketplace technology; our ability to continue to expand outside of the United States in compliance with local laws and regulations; our business model generally and our utilization of the proceeds from this offering; acceptance of the products and services that we market; the viability of our current intellectual property; government regulations and our ability to comply with government regulations; our ability to retain key employees; adverse changes in general market conditions for biospecimens; our ability to generate cash flow and profitability and continue as a going concern; our future financing plans; and our ability to adapt to changes in market conditions which could impair our operations and financial performance. These forward-looking statements involve numerous risks and uncertainties. Although we believe that our expectations expressed in these forward-looking statements are reasonable, our expectations may later be found to be incorrect. Our actual results of operations or the results of other matters that we anticipate could be materially different from our expectations. Important risks and factors that could cause our actual results to be materially different from our expectations are generally set forth in "Risk Factors," "Management's Discussion and Analysis of Financial Condition and Results of Operations," "Business," "Regulation" and other sections included or incorporated by reference in this prospectus. You should thoroughly read this prospectus and the documents incorporated herein by re

View Full Filing

View this S-1/A filing on SEC EDGAR